Pfizer (NYSE:PFE) Stock Rating Reaffirmed by Credit Suisse Group

Pfizer (NYSE:PFE)‘s stock had its “hold” rating restated by Credit Suisse Group in a research report issued on Wednesday, AnalystRatings.com reports. They currently have a $41.30 price objective on the biopharmaceutical company’s stock. Credit Suisse Group’s price objective suggests a potential upside of 11.47% from the company’s previous close.

A number of other research analysts have also recently issued reports on the company. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. UBS Group reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Pfizer in a report on Tuesday, October 29th. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Morgan Stanley cut their price target on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Nine investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Pfizer presently has an average rating of “Hold” and a consensus target price of $44.02.

Shares of NYSE:PFE traded up $0.14 on Wednesday, hitting $37.05. The stock had a trading volume of 24,924,227 shares, compared to its average volume of 23,366,957. Pfizer has a twelve month low of $33.97 and a twelve month high of $46.47. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The firm’s 50 day moving average price is $36.62 and its 200-day moving average price is $39.26. The company has a market capitalization of $207.30 billion, a price-to-earnings ratio of 12.35, a price-to-earnings-growth ratio of 2.11 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.13. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $12.37 billion. During the same quarter in the previous year, the company earned $0.78 EPS. The firm’s revenue for the quarter was down 4.6% compared to the same quarter last year. As a group, sell-side analysts predict that Pfizer will post 2.96 EPS for the current year.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, with a total value of $900,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the company’s stock in a transaction on Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $104,160. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

A number of large investors have recently made changes to their positions in PFE. 1 North Wealth Services LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at about $29,000. Bourgeon Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter valued at about $32,000. Salomon & Ludwin LLC increased its stake in shares of Pfizer by 362.7% in the 3rd quarter. Salomon & Ludwin LLC now owns 893 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 700 shares during the last quarter. Evolution Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at about $34,000. Finally, IMA Wealth Inc. increased its stake in shares of Pfizer by 144.5% in the 2nd quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 477 shares during the last quarter. 71.52% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is Elliott Wave theory?

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.